Annual report
4572.TEDINET S100T2Q7
Period2023-01-01 → 2023-12-31
Filed2024-03-27
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 137
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.6bn | 2023-01-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥1.4bn | 2022-01-01 → 2022-12-31 | Cons. | Net sales |
| Revenue | ¥2.0bn | 2021-01-01 → 2021-12-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.1bn | 2020-01-01 → 2020-12-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥3.2bn | 2019-01-01 → 2019-12-31d | Cons. | Net sales (5-year summary) |
| Operating income | −¥1.1bn | 2023-01-01 → 2023-12-31 | Cons. | Operating income |
| Operating income | −¥1.3bn | 2022-01-01 → 2022-12-31 | Cons. | Operating income |
| Ordinary income | −¥1.1bn | 2023-01-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | −¥1.3bn | 2022-01-01 → 2022-12-31 | Cons. | Ordinary income |
| Ordinary income | −¥523m | 2021-01-01 → 2021-12-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.1bn | 2020-01-01 → 2020-12-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥957m | 2019-01-01 → 2019-12-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | −¥1.1bn | 2023-01-01 → 2023-12-31 | Cons. | Income before income taxes |
| Profit before tax | −¥1.3bn | 2022-01-01 → 2022-12-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥1.2bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.3bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥534m | 2021-01-01 → 2021-12-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥1.1bn | 2020-01-01 → 2020-12-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥828m | 2019-01-01 → 2019-12-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | −¥1.2bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss |
| Net income | −¥1.3bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss |
| Total assets | ¥4.3bn | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥4.3bn | at 2022-12-31 | Cons. | Assets |
| Total assets | ¥5.4bn | at 2021-12-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥4.8bn | at 2020-12-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥5.4bn | at 2019-12-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥472m | at 2023-12-31 | Cons. | Liabilities |
| Total liabilities | ¥625m | at 2022-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥3.9bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥3.6bn | at 2022-12-31 | Cons. | Net assets |
| Net assets / equity | ¥4.3bn | at 2021-12-31d | Cons. | Net assets |
| Net assets / equity | ¥3.8bn | at 2020-12-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥3.9bn | at 2019-12-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.9bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.4bn | at 2022-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.9bn | at 2023-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.4bn | at 2022-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.8bn | at 2021-12-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.3bn | at 2020-12-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥4.9bn | at 2019-12-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥1.7bn | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥708m | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.5bn | 2021-01-01 → 2021-12-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥1.3bn | 2020-01-01 → 2020-12-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.5bn | 2019-01-01 → 2019-12-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥11m | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥126m | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥42m | 2021-01-01 → 2021-12-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥70m | 2020-01-01 → 2020-12-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥41m | 2019-01-01 → 2019-12-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥1.2bn | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥367m | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.1bn | 2021-01-01 → 2021-12-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥724m | 2020-01-01 → 2020-12-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥2.1bn | 2019-01-01 → 2019-12-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-68.62 | 2023-01-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-99.1 | 2022-01-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-42.1 | 2021-01-01 → 2021-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-90.33 | 2020-01-01 → 2020-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥76.05 | 2019-01-01 → 2019-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥74.51 | 2019-01-01 → 2019-12-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥226.16 | at 2023-12-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥255.04 | at 2022-12-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥323.54 | at 2021-12-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥308.05 | at 2020-12-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥329.86 | at 2019-12-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 89.1% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 85.0% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 79.3% | at 2021-12-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 79.0% | at 2020-12-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 71.5% | at 2019-12-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 35.1% | 2019-01-01 → 2019-12-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 67 | at 2023-12-31 | Cons. | Number of employees |
| Employees | 65 | at 2022-12-31 | Cons. | Number of employees |
| Employees | 64 | at 2021-12-31d | Cons. | Number of employees |
| Employees | 64 | at 2020-12-31d | Cons. | Number of employees |
| Employees | 63 | at 2019-12-31d | Cons. | Number of employees |
| Revenue | ¥1.5bn | 2023-01-01 → 2023-12-31 | Standalone | Net sales |
| Revenue | ¥1.2bn | 2022-01-01 → 2022-12-31 | Standalone | Net sales |
| Revenue | ¥1.9bn | 2021-01-01 → 2021-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥1.0bn | 2020-01-01 → 2020-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥3.1bn | 2019-01-01 → 2019-12-31d | Standalone | Net sales (5-year summary) |
| Operating income | −¥1.2bn | 2023-01-01 → 2023-12-31 | Standalone | Operating income |
| Operating income | −¥1.3bn | 2022-01-01 → 2022-12-31 | Standalone | Operating income |
| Ordinary income | −¥1.2bn | 2023-01-01 → 2023-12-31 | Standalone | Ordinary income |
| Ordinary income | −¥1.4bn | 2022-01-01 → 2022-12-31 | Standalone | Ordinary income |
| Ordinary income | −¥549m | 2021-01-01 → 2021-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.1bn | 2020-01-01 → 2020-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥874m | 2019-01-01 → 2019-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥1.2bn | 2023-01-01 → 2023-12-31 | Standalone | Income before income taxes |
| Profit before tax | −¥1.4bn | 2022-01-01 → 2022-12-31 | Standalone | Income before income taxes |
| Net income | −¥1.2bn | 2023-01-01 → 2023-12-31 | Standalone | Profit loss |
| Net income | −¥1.4bn | 2022-01-01 → 2022-12-31 | Standalone | Profit loss |
| Net income | −¥556m | 2021-01-01 → 2021-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥1.1bn | 2020-01-01 → 2020-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥746m | 2019-01-01 → 2019-12-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥4.1bn | at 2023-12-31 | Standalone | Assets |
| Total assets | ¥4.0bn | at 2022-12-31 | Standalone | Assets |
| Total assets | ¥5.3bn | at 2021-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥4.7bn | at 2020-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥5.3bn | at 2019-12-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥462m | at 2023-12-31 | Standalone | Liabilities |
| Total liabilities | ¥607m | at 2022-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥3.6bn | at 2023-12-31 | Standalone | Net assets |
| Net assets / equity | ¥3.4bn | at 2022-12-31 | Standalone | Net assets |
| Net assets / equity | ¥4.2bn | at 2021-12-31d | Standalone | Net assets |
| Net assets / equity | ¥3.7bn | at 2020-12-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥3.8bn | at 2019-12-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.6bn | at 2023-12-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥3.1bn | at 2022-12-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥-70.53 | 2023-01-01 → 2023-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-103.2 | 2022-01-01 → 2022-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-43.83 | 2021-01-01 → 2021-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-91.84 | 2020-01-01 → 2020-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥68.47 | 2019-01-01 → 2019-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥67.08 | 2019-01-01 → 2019-12-31d | Standalone | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥211.43 | at 2023-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥240.82 | at 2022-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥314.45 | at 2021-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥301.39 | at 2020-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥323.68 | at 2019-12-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 88.7% | at 2023-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.6% | at 2022-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.9% | at 2021-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.7% | at 2020-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 71.1% | at 2019-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 32.0% | 2019-01-01 → 2019-12-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 17,151,900 | at 2023-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 14,218,300 | at 2022-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 13,313,400 | at 2021-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 12,407,100 | at 2020-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 11,654,500 | at 2019-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 64 | at 2023-12-31 | Standalone | Number of employees |
| Employees | 62 | at 2022-12-31 | Standalone | Number of employees |
| Employees | 61 | at 2021-12-31d | Standalone | Number of employees |
| Employees | 61 | at 2020-12-31d | Standalone | Number of employees |
| Employees | 60 | at 2019-12-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 42
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment assets | at 2023-12-31 | ¥2.7bn |
| Drug Discovery Businessreportable segment | capex | 2023-01-01 → 2023-12-31 | ¥5m |
| Drug Discovery Businessreportable segment | depreciation | 2023-01-01 → 2023-12-31 | ¥12m |
| Drug Discovery Businessreportable segment | employees | at 2023-12-31 | 34 pure |
| Drug Discovery Businessreportable segment | revenue | 2023-01-01 → 2023-12-31 | ¥708m |
| Drug Discovery Businessreportable segment | revenue external | 2023-01-01 → 2023-12-31 | ¥708m |
| Drug Discovery Businessreportable segment | segment assets | at 2023-12-31 | ¥1.0bn |
| Drug Discovery Businessreportable segment | segment profit | 2023-01-01 → 2023-12-31 | −¥1.3bn |
| Drug Discovery Support Businessreportable segment | capex | 2023-01-01 → 2023-12-31 | ¥39m |
| Drug Discovery Support Businessreportable segment | depreciation | 2023-01-01 → 2023-12-31 | ¥23m |
| Drug Discovery Support Businessreportable segment | employees | at 2023-12-31 | 24 pure |
| Drug Discovery Support Businessreportable segment | revenue | 2023-01-01 → 2023-12-31 | ¥918m |
| Drug Discovery Support Businessreportable segment | revenue external | 2023-01-01 → 2023-12-31 | ¥918m |
| Drug Discovery Support Businessreportable segment | segment assets | at 2023-12-31 | ¥633m |
| Drug Discovery Support Businessreportable segment | segment profit | 2023-01-01 → 2023-12-31 | ¥226m |
| —segment total | capex | 2023-01-01 → 2023-12-31 | ¥45m |
| —segment total | depreciation | 2023-01-01 → 2023-12-31 | ¥36m |
| —segment total | revenue | 2023-01-01 → 2023-12-31 | ¥1.6bn |
| —segment total | revenue external | 2023-01-01 → 2023-12-31 | ¥1.6bn |
| —segment total | segment assets | at 2023-12-31 | ¥1.7bn |
| —segment total | segment profit | 2023-01-01 → 2023-12-31 | −¥1.1bn |
| Reconciling Itemsreconciling | segment assets | at 2022-12-31 | ¥3.2bn |
| Drug Discovery Businessreportable segment | capex | 2022-01-01 → 2022-12-31 | ¥68m |
| Drug Discovery Businessreportable segment | depreciation | 2022-01-01 → 2022-12-31 | ¥13m |
| Drug Discovery Businessreportable segment | revenue | 2022-01-01 → 2022-12-31 | ¥286m |
| Drug Discovery Businessreportable segment | revenue external | 2022-01-01 → 2022-12-31 | ¥286m |
| Drug Discovery Businessreportable segment | segment assets | at 2022-12-31 | ¥373m |
| Drug Discovery Businessreportable segment | segment profit | 2022-01-01 → 2022-12-31 | −¥1.7bn |
| Drug Discovery Support Businessreportable segment | capex | 2022-01-01 → 2022-12-31 | ¥58m |
| Drug Discovery Support Businessreportable segment | depreciation | 2022-01-01 → 2022-12-31 | ¥21m |
| Drug Discovery Support Businessreportable segment | revenue | 2022-01-01 → 2022-12-31 | ¥1.1bn |
| Drug Discovery Support Businessreportable segment | revenue external | 2022-01-01 → 2022-12-31 | ¥1.1bn |
| Drug Discovery Support Businessreportable segment | segment assets | at 2022-12-31 | ¥685m |
| Drug Discovery Support Businessreportable segment | segment profit | 2022-01-01 → 2022-12-31 | ¥453m |
| —segment total | capex | 2022-01-01 → 2022-12-31 | ¥126m |
| —segment total | depreciation | 2022-01-01 → 2022-12-31 | ¥34m |
| —segment total | revenue | 2022-01-01 → 2022-12-31 | ¥1.4bn |
| —segment total | revenue external | 2022-01-01 → 2022-12-31 | ¥1.4bn |
| —segment total | segment assets | at 2022-12-31 | ¥1.1bn |
| —segment total | segment profit | 2022-01-01 → 2022-12-31 | −¥1.3bn |
| Drug Discovery Businessreportable segment | employees | at 2023-12-31 | 33 pure |
| Drug Discovery Support Businessreportable segment | employees | at 2023-12-31 | 22 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,305
| Item | Context | Value | Unit |
|---|---|---|---|
| Commission fee sga | CurrentYearDuration_NonConsolidatedMember | 114485000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)有価証券報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条第1項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)近畿財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-03-27 | |
| Fiscal year cover page | FilingDateInstant | Original text (Japanese)第21期(自 2023年1月1日 至 2023年12月31日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)カルナバイオサイエンス株式会社 | |
| Company name in english cover page | FilingDateInstant | Carna Biosciences, Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 吉野公一郎 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)神戸市中央区港島南町一丁目5番5号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)078-302-7039(代表) | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)取締役経営管理本部長 山本詠美 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)神戸市中央区港島南町一丁目5番5号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)078-302-7039(代表) | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)取締役経営管理本部長 山本詠美 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E00987 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 45720 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)カルナバイオサイエンス株式会社 | |
| Filer name in english | FilingDateInstant | Carna Biosciences, Inc. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第三号様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Current fiscal year start date | FilingDateInstant | 2023-01-01 | |
| Current period end date | FilingDateInstant | 2023-12-31 | |
| Type of current period | FilingDateInstant | FY | |
| Current fiscal year end date | FilingDateInstant | 2023-12-31 | |
| Previous fiscal year start date | FilingDateInstant | 2022-01-01 | |
| Comparative period end date | FilingDateInstant | 2022-12-31 | |
| Previous fiscal year end date | FilingDateInstant | 2022-12-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Business results of reporting company (text) | FilingDateInstant | Text · Plus | |
| Company history (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Overview of affiliated entities (text) | FilingDateInstant | Text · Plus | |
| Information about employees (text) | FilingDateInstant | Text · Plus | |
| Business policy business environment issues to address etc (text) | FilingDateInstant | Text · Plus | |
| Disclosure of sustainability related financial information (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |